Clinical observation of camrelizumab combined with sorafenib in the treatment of advanced liver cancer

ZOU Yubin; YANG Ling; XIAO Chijin

doi:10.6039/j.issn.1001-0408.2024.12.19

您当前的位置：

首页 >

文章列表页 >

Clinical observation of camrelizumab combined with sorafenib in the treatment of advanced liver cancer

更新时间：2024-06-25

- Clinical observation of camrelizumab combined with sorafenib in the treatment of advanced liver cancer
- ZHONGGUO YAOFANG Vol. 35, Issue 12, Pages: 1522-1526(2024)
- 作者机构：
  
  新余市人民医院肿瘤科，江西新余　338025
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.12.19
  CLC： R979.1
- Published：30 June 2024，
  
  Received：05 December 2023，
  
  Revised：23 May 2024，
扫描看全文
邹瑜斌,杨灵,肖池金.卡瑞利珠单抗联合索拉非尼治疗晚期肝癌的临床观察 ^Δ[J].中国药房,2024,35(12):1522-1526.

ZOU Yubin,YANG Ling,XIAO Chijin.Clinical observation of camrelizumab combined with sorafenib in the treatment of advanced liver cancer[J].ZHONGGUO YAOFANG,2024,35(12):1522-1526.
邹瑜斌,杨灵,肖池金.卡瑞利珠单抗联合索拉非尼治疗晚期肝癌的临床观察 ^Δ[J].中国药房,2024,35(12):1522-1526. DOI： 10.6039/j.issn.1001-0408.2024.12.19.

ZOU Yubin,YANG Ling,XIAO Chijin.Clinical observation of camrelizumab combined with sorafenib in the treatment of advanced liver cancer[J].ZHONGGUO YAOFANG,2024,35(12):1522-1526. DOI： 10.6039/j.issn.1001-0408.2024.12.19.

摘要

目的

观察卡瑞利珠单抗联合索拉非尼治疗晚期肝癌的临床疗效和安全性。

方法

选择我院2020年3月－2021年11月收治的60例晚期肝癌患者，将其按随机数字表法分为研究组和对照组，每组各30例。对照组患者给予甲苯磺酸索拉非尼片（0.4 g，bid，口服），研究组患者在对照组用药的基础上给予注射用卡瑞利珠单抗（200 mg，每3周1次，静脉滴注），所有患者均治疗至疾病进展或发生不可耐受的副反应时停止治疗。比较两组患者的临床疗效、无进展生存期（PFS）、总生存期（OS）、1年生存率，记录两组患者治疗期间的不良反应及研究组患者的免疫相关不良事件发生情况。

结果

研究组患者的客观缓解率显著高于对照组（36.7%vs 13.3%，

＜0.05），中位OS和中位PFS均显著长于对照组（OS：12.6个月 vs 7.9个月；PFS：8.2个月 vs 5.3个月，

＜0.05）。两组患者的1年生存率及天冬氨酸转氨酶和丙氨酸转氨酶升高、皮疹或皮肤瘙痒、食欲减退、腹泻、乏力、高血压发生率比较，差异均无统计学意义（

＞0.05）。研究组患者发生的免疫治疗相关不良事件主要包括反应性毛细血管增生症21例（70.0%）、甲状腺功能减退6例（20.0%）、免疫相关性肺炎1例（3.3%），经对症治疗后均有所好转或可耐受。

结论

卡瑞利珠单抗联合索拉非尼可有效控制和延缓晚期肝癌患者的病情进展，延长患者生存时间，且不良反应可耐受。

Abstract

OBJECTIVE

To observe the clinical efficacy and safety of camrelizumab combined with sorafenib in the treatment of advanced liver cancer.

METHODS

Sixty patients with advanced liver cancer who were treated in our hospital from March 2020 to November 2021 were selected as the study subjects， and then were randomly divided into study group and control group， with 30 cases in each group. The control group was treated with Sorafenib tosylate tablets orally （0.4 g，bid）， and the study group was additionally given Camrelizumab for injection intravenously （200 mg， every 3 weeks） based on the control group； for all patients， the treatment was stopped until disease progression or intolerable side effects occurred. The clinical efficacy， progression-free survival （PFS）， total survival （OS） and 1-year survival rate of the two groups were compared， and the incidence of adverse reactions in two groups， and immune-related adverse reactions in the study group during treatment were recorded.

RESULTS

The objective remission rate of the study group was significantly higher than the control group （36.7% vs. 13.3%，

＜0.05）， and the median OS and median PFS were significantly longer than the control group （OS： 12.6 months vs. 7.9 months； PFS： 8.2 months vs. 5.3 months，

＜0.05）. There was no significant difference in the 1-year survival rate and the incidence of elevated aspartate aminotransferase and alanine aminotransferase， rash or pruritus， anorexia， diarrhea， fatigue and hypertension between the two groups （

＞0.05）. The adverse events immune-related in the study group mainly included 21 cases of reactive capillary hyperplasia （70.0%）， 6 cases of hypothyroidism （20.0%）， and 1 case of immune-associated pneumonia （3.3%）， which were improved or tolerable after symptomatic treatment.

CONCLUSIONS

Camrelizumab combined with sorafenib in the treatment of advanced liver cancer can effectively control and delay the disease progression， prolong the survival period of patients， and the adverse reactions can be tolerated.

关键词

索拉非尼卡瑞利珠单抗肝癌晚期生存期疗效安全性

Keywords

camrelizumabliver canceradvancedsurvival periodtherapeutic effectsafety

references

徐秋香，李红雨，周银华. 原发性肝癌患者疾病不确定感现状及其影响因素分析[J]. 癌症进展，2021，19（4）：426-429.

XU Q X，LI H Y，ZHOU Y H. Status of disease uncertainty in patients with primary liver cancer and its influen-cing factors[J]. Oncol Prog，2021，19（4）：426-429.

吕玲，邹威，陈晓明. 仑伐替尼治疗中晚期肝癌的研究进展[J]. 介入放射学杂志，2022，31（11）：1128-1131.

LYU L，ZOU W，CHEN X M. Research progress in lenvatinib for the treatment of mid-to-advanced hepatocellular carcinoma[J]. J Interv Radiol，2022，31（11）：1128-1131.

吴徐璐，陈炜越，郑丽云，等. 索拉非尼联合免疫检查点抑制剂治疗TACE抵抗的中晚期肝癌的疗效及安全性[J]. 肝胆胰外科杂志，2021，33（10）：585-589，595.

WU X L，CHEN W Y，ZHENG L Y，et al. Efficacy and safety of sorafenib combined with immune checkpoint inhibitors in TACE refractory liver cancer[J]. J Hepatopancreatobiliary Surg，2021，33（10）：585-589，595.

徐金发，宋文灿，郑中显，等. 国产细胞程序性死亡受体1抑制剂卡瑞利珠单抗联合阿帕替尼一线治疗中晚期原发性肝癌的疗效研究[J]. 中国全科医学，2022，25（26）：3258-3262.

XU J F，SONG W C，ZHENG Z X，et al. Efficacy of China-produced camrelizumab with apatinib for first-line treatment in middle and advanced stages of primary liver cancer[J]. Chin Gen Pract，2022，25（26）：3258-3262.

王瑛，袁鹤立，赵利，等. 清热利胆自拟方对仑伐替尼联合卡瑞丽珠单抗治疗晚期原发性肝癌患者炎症因子、免疫细胞水平和生活质量的影响[J]. 现代中西医结合杂志，2021，30（24）：2664-2669.

WANG Y，YUAN H L，ZHAO L，et al. Effect of self-made Qingre lidan decoction on inflammatory factors， immune cell levels and quality of life in patients with advanced primary liver cancer treated with lenvatinib combined with camrelizumab[J]. Mod J Integr Tradit Chin West Med，2021，30（24）：2664-2669.

饶耀，蒋德雄. 卡瑞丽珠单抗联合化疗对晚期肺腺癌患者血清肿瘤标志物水平及无疾病进展生存期的影响[J]. 中国处方药，2022，20（9）：103-105.

RAO Y，JIANG D X. Effect of tislelizumab combined with chemotherapy on serum tumor markers and survival time in patients with advanced lung adenocarcinoma[J]. J China Prescr Drug，2022，20（9）：103-105.

国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范：2019年版[J]. 临床肝胆病杂志，2020，36（2）：277-292.

Medical Administration of the State Health Commission.Guidelines for diagnosis and treatment of primary liver cancer in China：2019 edition[J]. J Clin Hepatol，2020，36（2）：277-292.

ADAM L C，SAVIC L J，CHAPIRO J，et al. Response assessment methods for patients with hepatic metastasis from rare tumor primaries undergoing transarterial chemoembolization[J]. Clin Imaging，2022，89：112-119.

FREITES-MARTINEZ A，SANTANA N，ARIAS-SANTIAGO S，et al. Using the common terminology criteria for adverse events（CTCAE - version 5.0）to evaluate the severity of adverse events of anticancer therapies[J]. Actas Dermosifiliogr，2021，112（1）：90-92.

中国临床肿瘤学会指南工作委员会组织. 中国临床肿瘤学会（CSCO）免疫检查点抑制剂相关的毒性管理指南2021[M]. 北京：人民卫生出版社，2021：33-89.

Organization of the Guidelines Working Committee of the Chinese Society of Clinical Oncology. Guidelines of Chinese Society of Clinical Oncology（CSCO）management of immune checkpoint inhibitor-related toxicity 2021[M]. Beijing：People’s Health Publishing House，2021：33-89.

罗志平. PD-1/PD-L1抑制剂联合分子靶向药物治疗中晚期肝癌的疗效和安全性分析[D]. 南昌：南昌大学，2020.

LUO Z P. Efficacy and safety of PD-1/PD-L1 inhibitors combined with molecular targeted drugs in the treatment of advanced liver cancer[D].Nanchang：Nanchang University，2020.

朱帝文，杨胜利，李一帆，等. 卡瑞利珠单抗联合索拉非尼治疗中晚期肝癌疗效分析[J]. 中华实用诊断与治疗杂志，2021，35（10）：1063-1067.

ZHU D W，YANG S L，LI Y F，et al. Efficacy of camrelizumab combined with sorafenib on advanced hepatocel-lular carcinoma[J]. J Chin Pract Diagn Ther，2021，35（10）：1063-1067.

欧惠仪，王越，彭承宏. PD-L1与Treg在肿瘤免疫及治疗中的相关性[J]. 国际肿瘤学杂志，2021，48（6）：350-353.

OU H Y，WANG Y，PENG C H. Correlation between PD-L1 and Tregs in tumor immunity and immunotherapy[J]. J Int Oncol，2021，48（6）：350-353.

位变，王华庆，柳凤亭，等. PD-1抑制剂卡瑞利珠单抗治疗恶性肿瘤引发反应性皮肤毛细血管增生二例[J]. 中华皮肤科杂志，2021，54（3）：252-253.

WEI B，WANG H Q，LIU F T，et al. Reactive cutaneous capillary endothelial proliferation caused by the PD-1 inhibitor camrelizumab during the treatment of malignant tumors：two case reports[J]. Chin J Dermatol，2021，54（3）：252-253.

CHAMBERLAIN C A，BENNETT E P，KVERNELAND A H，et al. Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy[J]. Mol Ther Oncolytics，2022，24：417-428.

刘演，胡宗涛，张永康，等. 基于TACE的多联治疗在中晚期肝细胞癌中疗效差异的回顾性研究[J]. 肝胆外科杂志，2023，31（3）：183-188.

LIU Y，HU Z T，ZHANG Y K，et al. Differential efficacy of TACE-based combination therapy in advanced hepatocellular carcinoma：a retrospective study[J]. J Hepato-biliary Surg，2023，31（3）：183-188.

汪国营，唐晖，张英才，等. 程序性死亡受体（PD）-1单克隆抗体治疗肝癌肝移植术后复发诱发急性免疫性肝炎：附1例报告[J]. 器官移植，2016，7（1）：44-47.

WANG G Y，TANG H，ZHANG Y C，et al. Programmed death receptor（PD）-1 monoclonal antibody-induced acute immune hepatitis in the treatment of recurrent hepatocel-lular carcinoma after liver transplantation：a case report[J]. Organ Transplant，2016，7（1）：44-47.

杨建奇，曹文淼，吴银霞，等. 卡瑞利珠单抗或信迪利单抗联合仑伐替尼治疗肝癌的效果及对肿瘤标志物的影响[J]. 肝脏，2022，27（10）：1080-1083.

YANG J Q，CAO W M，WU Y X，et al. The therapeutic effect of camrelizumab or sintilimab combined with lenvatinib in the treatment of liver cancer and the influence on tumor markers[J]. Chin Hepatol，2022，27（10）：1080-1083.

安文，沈俊颐，朱心睿，等. 仑伐替尼联合TACE和PD-1单抗治疗复发肝癌的安全性与有效性探索[J]. 中国普外基础与临床杂志，2022，29（10）：1289-1295.

AN W，SHEN J Y，ZHU X R，et al. Exploration of safety and efficacy of lenvatinib in combination with TACE and PD-1 antibody in treatment of recurrent liver cancer[J]. Chin J Bases Clin Gen Surg，2022，29（10）：1289-1295.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Meta-analysis of the effects of ABCB1 genotype on the efficacy and safety of taxanes in the treatment of breast cancer

Clinical observation of tofacitinib combined with hydroxychloroquine in the treatment of refractory rheumatoid arthritis

Meta-analysis of efficacy and safety of sedative therapy with midazolam and dexmedetomidine/propofol in critically ill patients undergoing mechanical ventilation

Efficacy and safety of tyrosine kinase inhibitors in the treatment of HER2-positive breast cancer： a meta-analysis

Efficacy and safety of domestic Paliperidone extended-release tablets in the treatment of stable schizophrenia

Related Author

ZHANG Shufang

LI Yan

LIU Lun

GENG Xiaoning

ZHOU Bo

ZHANG Zhongtao

LIU Fulei

WANG Mingjie

Related Institution

Dept. of Scientific Research， the Affiliated Taian City Central Hospital of Qingdao University， Shangdong Taian

Laboratory of Precision Intervention and Translational Medicine in Oncology， the Affiliated Taian City Central Hospital of Qingdao University， Shandong Taian

Dept. of Postdoctoral Workstation， the Affiliated Taian City Central Hospital of Qingdao University， Shandong Taian

Dept. of Clinical Pharmacy， the First Affiliated Hospital of Shandong First Medical University （Shandong Provincial Qianfoshan Hospital）

Dept. of Pharmacy， the Affiliated Taian City Central Hospital of Qingdao University， Shandong Taian

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰